Characteristics of complete responders; n = 31
Patient . | Age/sex . | Karyotype . | FLT3 abnormality . | History of secondary AML . | No. of cycles to CR . | CRD, mo . |
|---|---|---|---|---|---|---|
| 1 | 67/M | Diploid | — | — | 1 | 25.4+ |
| 2 | 54/M | Diploid | D835 | — | 1 | 22.2+ |
| 3 | 72/F | Diploid | — | — | 1 | 18.2+ |
| 4 | 62/M* | Diploid | — | NA | 1 | 17.8+ |
| 5 | 71/M | Diploid | — | + | 1 | 17.3+ |
| 6 | 66/F | Diploid | — | — | 1 | 15.5+ |
| 7 | 69/M | Diploid | — | — | 1 | 12.2+ |
| 8 | 53/M* | Diploid | — | NA | 1 | 9 |
| 9 | 70/F | Diploid | D835 | — | 1 | 7.6+ |
| 10 | 74/M | Diploid | — | + | 1 | 5.3 |
| 11 | 68/M | −Y | ITD | + | 1 | 5.1 |
| 12 | 72/M | Diploid | — | — | 1 | 4† |
| 13 | 74/F | Diploid | — | + | 1 | 3.9 |
| 14 | 61/F | inv(9) (constitutional) | ITD | — | 1 | 3.5 |
| 15 | 62/M | Diploid | — | — | 1 | 2.8 |
| 16 | 69/M | Diploid | — | — | 1 | 2† |
| 17 | 67/F | Diploid | — | — | 1 | 1‡ |
| 18 | 68/F | Diploid | ITD | — | 1 | 1.2 |
| 19 | 53/F | Complex, +8, +21 | — | — | 2 | 15.9+ |
| 20 | 59/M | −7 | ND | + | 1 | 15+ |
| 21 | 59/M* | +8 | ND | NA | 1 | 8.1 |
| 22 | 65/M | +8 | — | + | 1 | 6.5 |
| 23 | 65/M | Complex, del(5), +8 | — | + | 1 | 6.2 |
| 24 | 54/M* | Complex, −7 | — | NA | 1 | 6 |
| 25 | 55/F | +19 | — | + | 2 | 4.8 |
| 26 | 56/F | Complex, −5, −7 | ND | + | 1 | 3.2 |
| 27 | 66/M | t(1;6), del(3) | — | + | 1 | 2.5† |
| 28 | 57/F | Complex, −5, −7 | — | — | 1 | 2.3 |
| 29 | 67/M | i(14)(q10) | — | + | 1 | 1.6 |
| 30 | 56/M | Dup(1), +8 | — | — | 1 | 0.9 |
| 31 | 52/M | Complex, +8, del(11)(q23) | — | — | 1 | 0.5 |
Patient . | Age/sex . | Karyotype . | FLT3 abnormality . | History of secondary AML . | No. of cycles to CR . | CRD, mo . |
|---|---|---|---|---|---|---|
| 1 | 67/M | Diploid | — | — | 1 | 25.4+ |
| 2 | 54/M | Diploid | D835 | — | 1 | 22.2+ |
| 3 | 72/F | Diploid | — | — | 1 | 18.2+ |
| 4 | 62/M* | Diploid | — | NA | 1 | 17.8+ |
| 5 | 71/M | Diploid | — | + | 1 | 17.3+ |
| 6 | 66/F | Diploid | — | — | 1 | 15.5+ |
| 7 | 69/M | Diploid | — | — | 1 | 12.2+ |
| 8 | 53/M* | Diploid | — | NA | 1 | 9 |
| 9 | 70/F | Diploid | D835 | — | 1 | 7.6+ |
| 10 | 74/M | Diploid | — | + | 1 | 5.3 |
| 11 | 68/M | −Y | ITD | + | 1 | 5.1 |
| 12 | 72/M | Diploid | — | — | 1 | 4† |
| 13 | 74/F | Diploid | — | + | 1 | 3.9 |
| 14 | 61/F | inv(9) (constitutional) | ITD | — | 1 | 3.5 |
| 15 | 62/M | Diploid | — | — | 1 | 2.8 |
| 16 | 69/M | Diploid | — | — | 1 | 2† |
| 17 | 67/F | Diploid | — | — | 1 | 1‡ |
| 18 | 68/F | Diploid | ITD | — | 1 | 1.2 |
| 19 | 53/F | Complex, +8, +21 | — | — | 2 | 15.9+ |
| 20 | 59/M | −7 | ND | + | 1 | 15+ |
| 21 | 59/M* | +8 | ND | NA | 1 | 8.1 |
| 22 | 65/M | +8 | — | + | 1 | 6.5 |
| 23 | 65/M | Complex, del(5), +8 | — | + | 1 | 6.2 |
| 24 | 54/M* | Complex, −7 | — | NA | 1 | 6 |
| 25 | 55/F | +19 | — | + | 2 | 4.8 |
| 26 | 56/F | Complex, −5, −7 | ND | + | 1 | 3.2 |
| 27 | 66/M | t(1;6), del(3) | — | + | 1 | 2.5† |
| 28 | 57/F | Complex, −5, −7 | — | — | 1 | 2.3 |
| 29 | 67/M | i(14)(q10) | — | + | 1 | 1.6 |
| 30 | 56/M | Dup(1), +8 | — | — | 1 | 0.9 |
| 31 | 52/M | Complex, +8, del(11)(q23) | — | — | 1 | 0.5 |
— indicates absent; +, present; CRD, complete remission duration; D835, FLT3 mutation; NA, not applicable; ITD, internal tandem duplication; and ND, not done.
RAEB-2.
Taken off study in CR because of patient request (remission duration of patient no. 12: 16.2+ months; patient no. 16: 9 months; and patient no. 27: 20.3 months).
The patient died in CR.